Neurogene is targeting complex neurological diseases with precision gene therapies designed to optimize expression levels — a critical challenge in CNS indications. The company’s lead candidate, NGN-401, is in phase I trials for Rett syndrome and has received RMAT designation. With early data showing stable expression and no serious adverse events, Neurogene is also initiating trials in Angelman syndrome as part of its growing CNS pipeline.